Simalikalactone E (SkE), a New Weapon in the Armamentarium of Drugs Targeting Cancers That Exhibit Constitutive Activation of the ERK Pathway

Oncotarget - United States
doi 10.18632/oncotarget.791
Full Text
Abstract

Available in full text

Categories
Oncology
Date
Authors
Publisher

Impact Journals, LLC

Related search

Activation of the Hedgehog Pathway in Gastroesophageal Cancers

Journal of Solid Tumors
Cancer ResearchOncologyRadiologyNuclear MedicineImaging
2011English

Targeting the Akt/mTOR Pathway in Brca1-Deficient Cancers

Oncogene
Cancer ResearchGeneticsMolecular Biology
2011English

Baicalein Inhibits Melanogenesis Through Activation of the ERK Signaling Pathway

International Journal of Molecular Medicine
MedicineGenetics
2010English

OC-069 Constitutive Activation of the DNA Damage Response Pathway in Cancer Represents a Deregulated Pathway

Gut
Gastroenterology
2013English

Targeting the Ras/Raf/Mek/Erk Pathway in Hepatocellular Carcinoma (Review)

Oncology Letters
Cancer ResearchOncology
2017English

ERK Inhibitor LY3214996 Targets ERK Pathway-Driven Cancers: A Therapeutic Approach Toward Precision Medicine

Molecular Cancer Therapeutics
Cancer ResearchOncology
2019English

Activation of the MEK–S6 Pathway in High-Grade Ovarian Cancers

Applied Immunohistochemistry and Molecular Morphology
Forensic MedicinePathologyMedical Laboratory TechnologyHistology
2010English

Targeting the PI3K/AKT/MTOR Pathway in KSHV-associated Cancers

Infectious Agents and Cancer
Cancer ResearchEpidemiologyOncologyInfectious Diseases
2009English

Targeting the ERK Pathway Reduces Liver Metastasis of Smad4-Inactivated Colorectal Cancer

Cancer Biology and Therapy
Cancer ResearchOncologyMolecular MedicinePharmacology
2013English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy